Optimizing Peptide Nasal Drug Delivery: Science and Strategy

The nose is more than just a breathing organ. It is a direct pathway to the bloodstream and, in some cases, to the brain. Nasal drug delivery has long been used for small molecules like decongestants and allergy sprays. Now, researchers are working to make it a reliable route for delivering peptide drugs, which are much harder to administer than traditional small-molecule pharmaceuticals.

Why Consider the Nasal Route for Peptides?

Peptide drugs are almost always given by injection. This is because peptides break down in the digestive system before they can be absorbed. Injections bypass this problem but are inconvenient, painful, and require trained administration.

Nasal delivery offers a non-invasive alternative. The nasal mucosa has a rich blood supply, and drugs absorbed there enter the bloodstream directly without going through the liver first. This makes it one of the most promising non-injection routes for peptide drug delivery.

"The nasal cavity offers a unique window to the brain that bypasses the blood-brain barrier, making it an unparalleled route for CNS-targeted peptide therapeutics.", Lisbeth Illum, Professor of Pharmaceutical Sciences, Advanced Drug Delivery Reviews (2000)

Anatomy of the Nasal Cavity Relevant to Drug Delivery

The nasal cavity is divided into different regions, each with different properties for drug absorption. Understanding these regions is essential for designing effective nasal formulations.

The nasal vestibule (front part of the nose) is lined with skin-like tissue and does not absorb drugs well. The respiratory region is the main absorptive area for systemically acting drugs.

The olfactory region, located at the roof of the nasal cavity, is important for drug delivery directly to the brain. Drugs deposited here can travel along olfactory nerve fibers and enter the central nervous system without crossing the blood-brain barrier.

Oxytocin, a peptide hormone that affects social bonding and trust, has been extensively studied as a nasal spray. Intranasal oxytocin can reach the brain within minutes of administration, bypassing the need for injection and the blood-brain barrier.

The human nasal cavity has a surface area of about 150 square centimeters lined with highly vascularized tissue, yet most nasal sprays deposit drugs in regions with the lowest absorption potential.

Major Barriers to Nasal Peptide Absorption

Despite its advantages, nasal delivery is challenging for peptides. Several physical and biological barriers reduce how much drug actually reaches the bloodstream.

Mucociliary Clearance

The nasal mucosa is covered by a layer of mucus that traps particles and is constantly moved toward the throat by tiny hair-like structures called cilia. This mucociliary clearance removes foreign particles quickly, typically within 15 to 20 minutes.

For a peptide drug deposited in the nose, this means it must be absorbed before it is swept away. Most of what is not absorbed is swallowed and then degraded in the stomach.

Enzymatic Degradation

The nasal mucosa contains many enzymes that break down peptides, including aminopeptidases, endopeptidases, and proteases. These enzymes can degrade a peptide before it has time to cross the mucosal epithelium into the bloodstream.

Peptide stability against these enzymes is a major factor in whether nasal delivery is feasible for a given drug. Modifications like D-amino acid substitution and cyclization can protect peptides from nasal enzyme degradation.

The Epithelial Barrier

The nasal epithelium is a layer of tightly connected cells that regulates what crosses from the nasal cavity into the blood. Most peptides are too large and too hydrophilic to cross this barrier easily on their own.

Paracellular transport, which moves molecules through the tiny gaps between cells, is restricted by tight junction proteins. Transcellular transport, which moves molecules directly through cells, requires lipophilicity or specific carriers.

Strategies to Improve Nasal Peptide Absorption

Researchers have developed many strategies to overcome these barriers. The right combination of strategies can transform a poorly absorbed nasal peptide into one that reaches the bloodstream in therapeutically relevant amounts.

Absorption Enhancers

Absorption enhancers are substances that temporarily open the tight junctions between epithelial cells or fluidize cell membranes to allow more drug to pass through. They are one of the most widely studied strategies for improving nasal peptide bioavailability.

Chitosan, cyclodextrins, surfactants, and bile salts have all been tested as nasal absorption enhancers. Chitosan is a natural polymer derived from chitin that carries a positive charge and adheres to the negatively charged nasal mucosa, simultaneously improving contact time and opening tight junctions.

Mucoadhesive Formulations

Mucoadhesive formulations stick to the nasal mucosa and resist mucociliary clearance. This extends the time the drug stays in the nose, giving it more opportunity to be absorbed.

Polymers like hydroxypropyl methylcellulose (HPMC), carbopol, and hyaluronic acid are used to create mucoadhesive gels and microsphere formulations. These materials bind to the mucus layer and hold the drug in place far longer than a simple liquid spray.

Nanoparticle Carriers

Nanoparticles protect peptides from enzymatic degradation and can be taken up by nasal epithelial cells through endocytosis. Lipid nanoparticles, PLGA nanoparticles, and chitosan nanoparticles have all been studied for nasal peptide delivery.

Nanoparticles can also be surface-coated with targeting ligands that direct them to specific cell types in the nasal mucosa. This level of precision is useful for delivering drugs to the olfactory region for brain targeting.

When evaluating nasal peptide formulations, prioritize mucoadhesive excipients that extend contact time in the respiratory region, as mucociliary clearance can remove non-adhering formulations within 15 to 20 minutes.

Nasal-to-Brain Drug Delivery: The Olfactory Route

One of the most exciting applications of nasal drug delivery is the direct nose-to-brain pathway. Drugs deposited in the upper nasal cavity, near the olfactory epithelium, can travel along olfactory nerve axons into the brain.

This route bypasses the blood-brain barrier entirely. It allows peptides that would never cross the BBB on their own to reach brain tissue in meaningful concentrations.

Applications in Neurological Disease

Intranasal insulin has been extensively studied for Alzheimer's disease. Insulin receptors in the brain are involved in synaptic function and glucose metabolism. Delivering insulin directly to the brain via the nasal route has shown cognitive improvements in Phase II clinical trials.

Intranasal desmopressin, a peptide analog of vasopressin, is already approved and widely used for treating diabetes insipidus and bedwetting. This is one of the best-established examples of a clinically successful intranasal peptide product.

Device Design and Formulation Considerations

The device used to deliver a nasal drug has a major impact on where the drug deposits and how well it is absorbed. Standard nasal sprays deposit most of the dose in the anterior nasal cavity, which is the least absorptive region.

Specialized Delivery Devices

Devices designed to deposit drug deeper in the nasal cavity, such as the Optinose bi-directional breath-powered device, significantly improve bioavailability compared to standard pumps. These devices use breath force to propel the spray past the nasal valve into the respiratory and olfactory regions.

Research comparing standard nasal spray devices with improved ones shows two to five times higher bioavailability for peptides with the specialized devices. Device selection is now considered as important as formulation in nasal peptide product development.

Powder vs. Liquid Formulations

Liquid nasal sprays are the most common form, but peptide powders offer some advantages. Lyophilized (freeze-dried) peptide powders are more stable and do not require preservatives that can irritate the nasal mucosa.

Nasal powder devices have been developed for rapid drug delivery in emergency settings. Intranasal naloxone for opioid overdose reversal is already on the market and has saved thousands of lives, demonstrating the clinical potential of intranasal peptide-like drug delivery.

Current Pipeline of Intranasal Peptide Drugs

Several peptide drugs are currently in clinical development specifically for the nasal route. These include peptide treatments for migraine, pain, anxiety, and neurological conditions.

Intranasal oxytocin has been in more than 100 clinical studies. Several trials are ongoing in autism spectrum disorder, social anxiety disorder, and schizophrenia. Results have been mixed but encouraging enough to maintain significant research interest.

For related reading on delivering peptides to the brain through other methods, see our article on how peptides cross the blood-brain barrier. You can also learn how lipidation improves delivery across biological membranes in our post on peptide lipidation and drug delivery advances.

For clinical trial information on intranasal peptide therapies, the ClinicalTrials.gov database lists all registered trials including those investigating intranasal routes for peptide drugs.

Nasal peptide delivery success depends on matching the right combination of absorption enhancer, formulation type, and device design to target the optimal nasal region for your specific peptide's molecular profile.

FAQs

Why are peptide drugs usually given by injection? Peptides break down in the digestive system and cannot be absorbed intact from the gut in most cases. Injection delivers the drug directly into the bloodstream, bypassing this problem.

What are the advantages of nasal drug delivery for peptides? Nasal delivery is non-invasive, avoids first-pass liver metabolism, has rapid absorption, and provides a direct route to the brain for some peptides. It is more convenient than injection and preferred by patients.

What is mucociliary clearance and why does it matter for nasal delivery? Mucociliary clearance is the process by which cilia in the nose move mucus toward the throat, removing foreign particles. It limits how long a drug stays in the nose, reducing absorption time. Mucoadhesive formulations help extend this contact time.

What is the olfactory route to the brain? Drugs deposited near the olfactory epithelium in the upper nasal cavity can travel along olfactory nerve fibers directly into the brain. This bypasses the blood-brain barrier and is being studied for treating neurological diseases.

What are absorption enhancers in nasal formulations? Absorption enhancers are substances added to nasal formulations to improve drug absorption. They work by temporarily opening tight junctions between epithelial cells or making cell membranes more permeable. Examples include chitosan, cyclodextrins, and bile salts.

Are any nasal peptide drugs already approved? Yes. Desmopressin nasal spray for diabetes insipidus and nasal calcitonin for osteoporosis are long-approved examples. Newer examples include intranasal naloxone for opioid overdose, though this is a small molecule rather than a traditional peptide.